Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours

Abstract

Chk2 is a transducer of DNA damage signals and a tumour suppressor whose germ-line mutations predispose to diverse tumour types. Unlike its downstream targets such as the p53 tumour suppressor, the expression patterns of Chk2 in tissues and tumours remain unknown. As DNA breaks occur commonly during gametogenesis, and p53 is wild-type and overexpressed in testicular cancer, we examined abundance and localisation of the Chk2 protein during normal development of human testes, and at various stages of germ-cell tumour (GCT) pathogenesis. Our results show that Chk2 is abundant in foetal germ cells and adult spermatogonia, yet only weakly expressed or lacking during the meiotic and later stages of spermatogenesis. High levels of Chk2 are detected in the majority of GCTs including all pre-invasive carcinoma-in-situ lesions, contrary to variable expression and even lack of Chk2 in subsets of invasive GCTs and some teratoma structures, respectively. Together with our analyses of cell culture models, these results indicate that downmodulation or lack of Chk2 is not simply attributable to quiescence or differentiation, they suggest a role for Chk2 in mitotic rather than meiotic divisions, support the concept of foetal origin of GCTs, and have implications for protein-based screening for tumour-associated aberrations of Chk2.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Andrews PW . 1984 Dev. Biol. 103: 285–293

  • Barlow C, Liyanage M, Moens PB, Deng C-X, Ried T, Wynshaw-Boris A . 1997 Nat. Genet. 17: 462–466

  • Bartkova J, Bartek J, Lukas J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Midgley CA, Lane DP . 1991 Int. J. Cancer 49: 196–202

  • Bartkova J, Thullberg M, Rajpert-De Meyts E, Skakkebæk NE, Bartek J . 2000a Oncogene 19: 4146–4150

  • Bartkova J, Thullberg M, Rajpert-De Meyts E, Skakkebæk NE, Bartek J . 2000b Int. J. Cancer 85: 370–375

  • Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA . 1999 Science 286: 2528–2531

  • Chaganti RSK, Houldsworth J . 2000 Cancer Res 60: 1475–1482

  • Chehab NH, Malikzay A, Appel M, Halazonetis TD . 2000 Genes Dev. 14: 278–288

  • Cressman VL, Backlund DC, Avrutskaya AV, Leadon SA, Godfrey V, Koller BH . 1999 Mol Cell Biol 19: 7061–7075

  • Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J . 2001 Nature 410: 842–847

  • Flaggs G, Plug AW, Dunks KM, Mundt KE, Ford JC, Quiggle MRE, Taylor EM, Westphal CH, Ashley T, Hoekstra MF, Carr AM . 1997 Curr. Biol. 7: 977–986

  • Grigor KM, Wylie CC . 1998 APMIS 106: 221–224

  • Hartley AL, Birch JM, Kelsey AM, Marsden HB, Harris M, Teare MD . 1989 Cancer Genet. Cytogenet 42: 221–226

  • Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW . 2000 Science 287: 1824–1827

  • Kaneko YS, Watanabe N, Morisaki H, Akita H, Fujimoto A, Tominaga K, Terasawa M, Tachibana A, Ikeda K, Nakanishi M, Kaneko Y . 1999 Oncogene. 18: 3673–3681

  • Lee JS, Collins KM, Brown AL, Lee CH, Chung JH . 2000 Nature 404: 201–204

  • Lutzker SG, Levine AJ . 1996 Nat. Med. 2: 804–810

  • Mailand N, Falck J, Lukas C, Syljuåsen RG, Welcker M, Bartek J, Lukas J . 2000 Science 288: 1425–1429

  • Matsuoka S, Huang M, Elledge SJ . 1998 Science 282: 1893–1897

  • May P, May E . 1999 Oncogene 18: 7621–7636

  • Pleasure SJ, Lee VM-Y . 1993 J. Neurosci. Res. 35: 585–602

  • Rotman G, Shiloh Y . 1999 Oncogene 18: 6135–6144

  • Rotter V, Schwartz D, Almon E, Goldfinger N, Kapon A, Meshorer A, Donehower LA, Levine AJ . 1993 Proc. Natl. Acad. Sci. USA 90: 9075–9079

  • Schwartz D, Goldfinger N, Kam Z, Rotter V . 1999 Cell Growth Diff. 10: 665–675

  • Scully R, Livingston DM . 2000 Nature 408: 429–432

  • Shieh S-Y, Ahn J, Tamai K, Taya Y, Prives C . 2000 Genes. Dev. 14: 289–300

  • Skakkebæk NE, Berthelsen JG, Giwercman A, Müller J . 1987 Int. J. Androl. 10: 19–28

  • Vogelstein B, Lane D, Levine AJ . 2000 Nature 408: 307–310

  • Zhou BB, Elledge SJ . 2000 Nature 408: 433–439

  • Zickler D, Kleckner N . 1999 Annu. Rev. Genet. 33: 603–754

Download references

Acknowledgements

We thank P Andrews, S Elledge, G Evan and Maxwell Sehested for providing important reagents, and the Danish Cancer Society, the Nordic Cancer Union, the European Commission, and the Danish Medical Research Council for grant support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jiri Bartek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartkova, J., Falck, J., Rajpert-De Meyts, E. et al. Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours. Oncogene 20, 5897–5902 (2001). https://doi.org/10.1038/sj.onc.1204746

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204746

Keywords

This article is cited by

Search

Quick links